1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsBiomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development is sponsored by Department of Health And Human Services. This opportunity supports mission-aligned projects and measurable outcomes.
Get alerted about grants like this
Save a search for “Department of Health And Human Services” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
A **. gov** website belongs to an official government organization in the United States.
* How to Apply for Grants * **Applicant Resources** * Adobe Software Compatibility * Submitting UTF-8 Special Characters * Encountering Error Messages * Grantor Standard Language * Submitting UTF-8 Special Characters * **Applicant System-To-System** * Reference Implementation * **Grantor System-To-System** * Reference Implementation * SF-424 Individual Family * SF-424 Mandatory Family * SF-424 Short Organization Family * Post-Award Reporting Forms * Country and State Lists Updates * **Manage Subscriptions** * Program Management Office * Grants.
gov Maintenance Calendar The Biomedical Advanced Research and Development Authority Special Projects Department of Health and Human Services Assistant Secretary for Preparedness and Response Document Type:Grants Notice Funding Opportunity Number:EP-IDS-15-002 Funding Opportunity Title:The Biomedical Advanced Research and Development Authority Special Projects Opportunity Category:Discretionary Opportunity Category Explanation: Funding Instrument Type:Cooperative Agreement Category of Funding Activity:Health Expected Number of Awards:1 Assistance Listings:93.
360 -- Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development Cost Sharing or Matching Requirement:No Last Updated Date:Jul 13, 2015 Original Closing Date for Applications:Sep 04, 2015 Application Deadline Date: September 4, 2015 at 11:59pm EST Current Closing Date for Applications:Sep 04, 2015 Application Deadline Date: September 4, 2015 at 11:59pm EST Archive Date:Oct 04, 2015 Estimated Total Program Funding:$ 200,000 Eligible Applicants:Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) Special district governments Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses City or township governments Additional Information on Eligibility:Non-domestic (non-U.S.) entity - Unless the authorizing legislation under which an award would be made specifically authorizes awards to foreign entities or the grant is for research (not research-related grants), foreign entities are not eligible for HHS grants ## Additional Information Agency Name:Assistant Secretary for Preparedness and Response Description:The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), supports advanced development and availability of medical countermeasures (MCMs) for chemical, biological, radiological and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases through advanced product development, stockpile acquisition, building manufacturing infrastructure, and product innovation.
BARDA establishes and maintains business collaborations by means of grants, cooperative agreements, contracts, and other transactions with the public and private sectors, domestically and internationally. BARDA has grown significantly since inception, acquiring new capabilities and employing new business approaches leading to unprecedented success in the development and acquisition of MCMs.
Twenty-one products supported by BARDA have received FDA approval, licensure or clearance against the threats within BARDAÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂâÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂs purview and twelve products have been procured under Project BioShield for the Strategic National Stockpile.
BARDA has also played a key role in responding to newly emerging threats, including most prominently the 2009-H1N1 influenza pandemic as well as the ongoing Ebola epidemic in West Africa.
The National Strategy for Combating Antibiotic Resistant Bacteria (2014) identifies BARDA as having a key role in the nationÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂâÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂs response to the more slowly, but inexorably emerging threat of antimicrobial resistance (AMR).
By their unpredictability and potentially explosive nature, emerging threats present unique challenges, particularly with respect to the development of MCMs, which normally takes years, requires substantial investment, and is associated with high rates of attrition. Many of the challenges are technical; some are economic.
The problem of AMR presents special hurdles in that the discovery of novel drug targets unique to the resistant pathogens has proved increasingly difficult.
Having a mechanism in place to engage external subject matter experts and develop far-reaching, but focused, technical reports that provide recommendations on how to address such challenges would facilitate progress in the development of MCMs against these national health security threats.
Link to Additional Information:The Biomedical Advanced Research and Development Authority Special Projects Grantor Contact Information:If you have difficulty accessing the full announcement electronically, please contact: Grants. gov Contact Center Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays.
Grants. gov Customer Support #### Health & Human Services * Frequently Asked Questions ## Your session will expire in 3 minutes. To continue working, click on the "OK" button below.
This is being done to protect your privacy. Unsaved changes will be lost.
Based on current listing details, eligibility includes: All types of entities are eligible, including highly qualified foreign nationals outside the United States either alone or in collaboration with American participants when such transactions may inure to the benefit of t… Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Recent federal obligations suggest $50,000 (2024). Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
Community Economic Development Planning Grants is sponsored by Administration for Children and Families (ACF), Office of Community Services (OCS), U.S. Department of Health and Human Services (HHS). This program stimulates new project development through administrative capacity building for Community Development Corporations (CDCs). This can be a good entry point for organizations to plan and develop projects that might later be eligible for larger CED project grants, potentially incorporating arts and cultural elements within a community economic development framework for urban youth.
Implementing Zero Suicide in Health Systems is sponsored by Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services. Implements the comprehensive Zero Suicide intervention and prevention model for adults within health systems. Requires application of seven framework elements: Lead, Train, Identify, Engage, Treat, Transition, and Improve.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.